CGEM Cullinan Therapeutics, Inc. Insider Trading

Lynx1 Capital bought 165,667 CGEM shares at $8.40 on 2025-10-28; now down 56.2% from 52-week high at $7.56 current price.

Lynx1 Capital, a 10% owner, purchased 165,667 shares at $8.40 on 2025-10-28, bringing total holdings to 8.96M shares. This represents a continuation of sustained buying activity—the insider executed 5 separate purchases at this ticker between 2025-10-10 and 2025-10-28, with outcomes not yet measurable. The stock is currently trading at $7.56, down 56.2% from its 52-week high of $17.27 and off 1.4% over the 90-day period. The company posted zero quarterly revenue, a $-70.1M net loss for the full year, and 100% annual revenue decline, signaling a pre-commercial or severely distressed business model. The repeated accumulation by a major shareholder during a period of steep valuation decline and operational deterioration suggests continued conviction despite fundamental headwinds, though the stock's sharp withdrawal from recent highs and the lack of measurable outcomes from same-ticker trades warrant close observation of both company execution and market sentiment shifts.

Lynx1 Capital (10% owner) bought 248,749 shares at avg $8.46 over 4 days; stock at $8.48, down 51.8% from 52-week high.

Lynx1 Capital executed 4 separate purchases totaling 248,749 shares for $2,103,912.00 between 2025-10-14 and 2025-10-17, with a blended average price of $8.46. The current stock price of $8.48 sits near the transaction price but represents a significant 51.8% decline from the 52-week high of $17.61, and the company's fundamentals remain deeply challenged: zero revenue in the latest quarter and negative $70,055,000.00 net income. Lynx1 has established a three-transaction pattern at CGEM within the prior week (buys on 2025-10-08, 2025-10-09, and 2025-10-10), suggesting sustained accumulation, though measurable outcomes from those earlier trades remain unavailable. The insider's cross-ticker track record shows strong historical returns (avg 30d return +550.5%, 90d return +526.6% with a 72.73% win rate), but this indicator cannot be projected onto the current CGEM transaction given the company's unprofitability, near-zero revenue, and negative annual revenue growth of -100.0%.

Lynx1 Capital (10% owner) bought 1,459,641 shares across 3 days (Oct 8–10) for $9.8M at blended avg $6.73, raising stake to 8.55M shares.

Lynx1 Capital Management LP, a significant 10% shareholder, executed 3 separate purchases totaling 1,459,641 shares for $9,826,941.41 at a blended average price of $6.73 between October 8–10, 2025, increasing its post-transaction holdings to 8,549,084 shares (8.55M shares) from 7,089,443 shares—a 20.6% increase in its stake. The purchases were made despite the company's severe financial distress: latest-quarter revenue is $0.00 and the company posted a $-70,055,000.00 net loss with -100.0% annual revenue growth, making it unprofitable. The current price of $7.40 sits -58.0% below the 52-week high of $17.61, with the stock up 14.4% over the prior 30 days. The insider's cross-ticker track record shows an average 90-day return of +638.2% and a 90d win rate of 66.67%, but this data reflects outcomes across multiple tickers and does not establish predictive accuracy for Cullinan Therapeutics specifically.